COVID-19 and Cardiovascular Disease : From Bench to Bedside
A pandemic of historic impact, coronavirus disease 2019 (COVID-19) has potential consequences on the cardiovascular health of millions of people who survive infection worldwide. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the etiologic agent of COVID-19, can infect the heart, vascular tissues, and circulating cells through ACE2 (angiotensin-converting enzyme 2), the host cell receptor for the viral spike protein. Acute cardiac injury is a common extrapulmonary manifestation of COVID-19 with potential chronic consequences. This update provides a review of the clinical manifestations of cardiovascular involvement, potential direct SARS-CoV-2 and indirect immune response mechanisms impacting the cardiovascular system, and implications for the management of patients after recovery from acute COVID-19 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
Circulation research - 128(2021), 8 vom: 16. Apr., Seite 1214-1236 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chung, Mina K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.04.2021 Date Revised 31.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCRESAHA.121.317997 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324116993 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324116993 | ||
| 003 | DE-627 | ||
| 005 | 20240331233509.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCRESAHA.121.317997 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1358.xml |
| 035 | |a (DE-627)NLM324116993 | ||
| 035 | |a (NLM)33856918 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chung, Mina K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and Cardiovascular Disease |b From Bench to Bedside |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2021 | ||
| 500 | |a Date Revised 31.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A pandemic of historic impact, coronavirus disease 2019 (COVID-19) has potential consequences on the cardiovascular health of millions of people who survive infection worldwide. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the etiologic agent of COVID-19, can infect the heart, vascular tissues, and circulating cells through ACE2 (angiotensin-converting enzyme 2), the host cell receptor for the viral spike protein. Acute cardiac injury is a common extrapulmonary manifestation of COVID-19 with potential chronic consequences. This update provides a review of the clinical manifestations of cardiovascular involvement, potential direct SARS-CoV-2 and indirect immune response mechanisms impacting the cardiovascular system, and implications for the management of patients after recovery from acute COVID-19 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a angiotensin-converting enzyme 2 | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a magnetic resonance imaging | |
| 650 | 4 | |a thrombosis | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a NRP1 protein, human |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Troponin |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Neuropilin-1 |2 NLM | |
| 650 | 7 | |a 144713-63-3 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Zidar, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Bristow, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Cameron, Scott J |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Harding, Clifford V |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Deborah H |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Tamanna |e verfasserin |4 aut | |
| 700 | 1 | |a Tilton, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Emily J |e verfasserin |4 aut | |
| 700 | 1 | |a Tucker, Nathan R |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard, John |e verfasserin |4 aut | |
| 700 | 1 | |a Loscalzo, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation research |d 1953 |g 128(2021), 8 vom: 16. Apr., Seite 1214-1236 |w (DE-627)NLM000001910 |x 1524-4571 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2021 |g number:8 |g day:16 |g month:04 |g pages:1214-1236 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCRESAHA.121.317997 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2021 |e 8 |b 16 |c 04 |h 1214-1236 | ||